Cue Biopharma (CUE) Common Equity (2017 - 2026)

Cue Biopharma has disclosed Common Equity across 10 years of filings, most recently posting $2.3 million for Q2 2026.

• In Q2 2026, Common Equity fell 87.28% year-over-year to $2.3 million; the TTM figure through Jun 2026 stood at $2.3 million (down 87.28% YoY), while the FY2025 annual figure was $26.4 million, up 51.05% from the prior year.
• Common Equity came in at $2.3 million for Q2 2026 at Cue Biopharma, down from $26.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $65.7 million in Q4 2022 to a low of $2.3 million in Q2 2026.
• Average Common Equity over 5 years is $34.3 million, with a median of $30.0 million recorded in 2024.
• Year-over-year, Common Equity soared 51.05% in 2025 and sank 87.28% in 2026.
• Over 5 years, Common Equity stood at $65.7 million in 2022, then tumbled by 43.54% to $37.1 million in 2023, then tumbled by 52.81% to $17.5 million in 2024, then soared by 51.05% to $26.4 million in 2025, then sank by 91.26% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $2.3 million in Q2 2026, $26.4 million in Q4 2025, and $13.2 million in Q3 2025.